We are live on ! Find out more
LSTA icon

Lisata Therapeutics
LSTA

22 hedge funds and large institutions have $2.51M invested in Lisata Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

21% more capital invested

Capital invested by funds: $2.08M → $2.51M (+$437K)

5% more funds holding

Funds holding: 21 → 22 (+1)

0.4% more ownership

Funds ownership: 8.14% → 8.54% (+0.4%)

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$62.5K
2
Morgan Stanley
Morgan Stanley
New York
+$45.7K
3
HighTower Advisors
HighTower Advisors
Illinois
+$36.5K
4
Renaissance Technologies
Renaissance Technologies
New York
+$3.27K
5
TRCT
Tower Research Capital (TRC)
New York
+$1.34K

Top Sellers

Rank Fund Capital Flow
1
PCFFS
Pacific Center for Financial Services
California
-$26
2
Osaic Holdings
Osaic Holdings
Arizona
-$7
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
1
BML Capital Management
Indiana
$902K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$652K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$345K +$3.27K +900 +1%
BlackRock
4
BlackRock
New York
$210K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$96.1K – – –
Citadel Advisors
6
Citadel Advisors
Florida
$63.6K +$62.5K +17,178 New
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$55.3K – – –
State Street
8
State Street
Massachusetts
$53.1K – – –
Morgan Stanley
9
Morgan Stanley
New York
$52.3K +$45.7K +12,574 +812%
CW
10
Cook Wealth
North Carolina
$38.4K – – –
HighTower Advisors
11
HighTower Advisors
Illinois
$37K +$36.5K +10,042 New
TRCT
12
Tower Research Capital (TRC)
New York
$3.92K +$1.34K +369 +53%
FCMT
13
Founders Capital Management (Texas)
Texas
$2.46K – – –
VNA
14
Valley National Advisers
Pennsylvania
$1K – – –
Wells Fargo
15
Wells Fargo
California
$115 +$7 +2 +7%
Barclays
16
Barclays
United Kingdom
$100 +$76 +21 +350%
Bank of America
17
Bank of America
North Carolina
$96 – – –
Northwestern Mutual Wealth Management
18
Northwestern Mutual Wealth Management
Wisconsin
$74 – – –
Fidelity Investments
19
Fidelity Investments
Massachusetts
$4 – – –
UBS Group
20
UBS Group
Switzerland
$4 – – –
Osaic Holdings
21
Osaic Holdings
Arizona
$3 -$7 -2 -67%
PCFFS
22
Pacific Center for Financial Services
California
– -$26 -8 Closed

LSTA Hedge Fund Activity: Q2 2023 in Review

22 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q2 2023, worth a combined $2.51M — up 21% from $2.08M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new LSTA positions and 1 closed out — a net gain of 1 holder — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $62.5K. The largest seller was Pacific Center for Financial Services, exiting entirely with an estimated $26 sold.

  • 22 institutional investors held Lisata Therapeutics (LSTA) as of Q2 2023, up from 21 in Q1 2023.
  • Funds reported $2.51M of Lisata Therapeutics stock for Q2 2023, up 21% quarter-over-quarter.
  • 2 funds opened new Lisata Therapeutics positions in Q2 2023 and 1 closed out, a net change of +1 holder.
  • The largest Lisata Therapeutics buyer in Q2 2023 was Citadel Advisors, an estimated $62.5K added.
  • The largest Lisata Therapeutics seller in Q2 2023 was Pacific Center for Financial Services, an estimated $26 sold.

Based on aggregated 13F filings for Q2 2023.